地西他滨联合化疗治疗骨髓增生异常综合征的疗效及安全性

Efficacy and Safety of Decitabine Combined with Chemotherapy in the Treatment of Myelodysplastic Syndrome

目的研究地西他滨联合化疗治疗骨髓增生异常综合症(MDS)的疗效及安全性。方法随机数表法将本院2015年1月-2018年3月诊治的90例MDS患者分为观察组与对照组,各45例,对照组给予化疗(高三尖杉酯碱、阿糖胞苷)治疗,观察组给予地西他滨联合化疗治疗。治疗3个月后评价疗效并观察用药期间的不良反应率以及治疗前后血细胞指标(白细胞、血红蛋白、血小板)变化。结果观察组治疗总有效率91.11%,显著高于对照组的66.67%(P<0.05);两组治疗后白细胞、血红蛋白、血小板数量比同组治疗前均显著上升,且观察组治疗后上升幅度明显大于对照组,差异有统计学意义(P<0.05);观察组不良反应发生率低于对照组,但差异无统计学意义(P>0.05)。结论地西他滨联合化疗治疗MDS患者安全有效。

Objective To study the efficacy and safety of decitabine combined with chemotherapy in the treatment of myelodysplastic syndrome(MDS).Methods 90 patients with MDS diagnosed in the hospital from January 2015 to March 2018 were divided into observation group and control group according to the random number table method,with 45 cases in each group.Control group was given chemotherapy(homoharringtonine,cytarabine),and observation group was given decitabine combined with chemotherapy.After 3 months of treatment,the efficacy was evaluated,and the rate of adverse reactions during medicine and changes of blood cell indexes(white blood cells,hemoglobin,platelets)before and after treatment were observed.Results The total effective rate of treatment in observation group was significantly higher than that in control group(91.11%vs 66.67%)(P<0.05).The quantities of white blood cells,hemoglobin and platelets in the two groups after treatment were significantly increased compared with those in the same group before treatment,and the increases in observation group after treatment were significantly greater than those in control group(P<0.05).The incidence rate of adverse reactions in observation group was lower than that in control group(P>0.05).Conclusion Decitabine combined with chemotherapy is safe and effective in the treatment of patients with MDS.